The VALID Act currently being debated in Congress would increase the regulatory burden on clinical laboratories. In this interview, Dr. David Grenache from TriCore Laboratories and the University of New Mexico, together with Dr. Vince Stine from the American Association for Clinical Chemistry, explain why VALID would slow down innovation while it raises costs, and why VALID appears to be designed to benefit a particular industry sector rather than patients.